|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0013090,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0025543,
umls-concept:C0178602,
umls-concept:C0205210,
umls-concept:C0205474,
umls-concept:C0473169,
umls-concept:C0948089,
umls-concept:C1274040,
umls-concept:C1423498,
umls-concept:C2290901
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-4-2
|
|
pubmed:abstractText |
Vulnerable plaque demonstrates intense inflammation in which macrophages secrete matrix metalloproteinases (MMPs) that degrade the fibrous cap, ultimately leading to rupture, in situ thrombosis, and an associated clinical event. Thus, inhibition of MMP activity or more general suppression of vascular inflammation are attractive targets for interventions intended to reduce plaque rupture. We hypothesized that subantimicrobial doses of doxycycline (SDD) (20 mg twice daily) would benefit patients with coronary artery disease by reducing inflammation and MMP activity and thus possibly prevent coronary plaque rupture events.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1524-4636
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
733-8
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14962945-Aged,
pubmed-meshheading:14962945-Angina, Unstable,
pubmed-meshheading:14962945-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:14962945-Arteriosclerosis,
pubmed-meshheading:14962945-Biological Markers,
pubmed-meshheading:14962945-C-Reactive Protein,
pubmed-meshheading:14962945-Coronary Artery Disease,
pubmed-meshheading:14962945-Death, Sudden, Cardiac,
pubmed-meshheading:14962945-Double-Blind Method,
pubmed-meshheading:14962945-Doxycycline,
pubmed-meshheading:14962945-Female,
pubmed-meshheading:14962945-Humans,
pubmed-meshheading:14962945-Inflammation,
pubmed-meshheading:14962945-Interleukins,
pubmed-meshheading:14962945-Male,
pubmed-meshheading:14962945-Matrix Metalloproteinase 9,
pubmed-meshheading:14962945-Matrix Metalloproteinases,
pubmed-meshheading:14962945-Middle Aged,
pubmed-meshheading:14962945-Myocardial Infarction,
pubmed-meshheading:14962945-Pilot Projects,
pubmed-meshheading:14962945-Prospective Studies,
pubmed-meshheading:14962945-Protease Inhibitors,
pubmed-meshheading:14962945-Rupture, Spontaneous,
pubmed-meshheading:14962945-Troponin I,
pubmed-meshheading:14962945-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial.
|
|
pubmed:affiliation |
Department of Medicine (Cardiology), Albert Einstein College of Medicine, Bronx, NY, USA. dabrown@chpnet.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|
